Aktieanalys

Xspray Pharma Q1 2025: All eyes on PDUFA - Redeye

{newsItem.title}

Redeye Publicerad: 08 May 11:37

Redeye comments on Xspray following an undramatic Q1 report. The key focus remains on the ongoing regulatory process and launch preparations for Dasynoc, alongside the continued clinical development of XS003.

Länk till analysen i sin helhet: https://www.redeye.se/research/1099962/xspray-pharma-q1-2025-all-eyes-on-pdufa?utm_source=finwire&utm_medium=RSS

Nyheter om Xspray Pharma

Läses av andra just nu

Om aktien Xspray Pharma

Senaste nytt